Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction that occurred on Friday, October 27th. The shares were bought at an average cost of $2.00 per share, with a total value of $800,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) opened at 2.15 on Tuesday. Sunesis Pharmaceuticals, Inc. has a 1-year low of $1.82 and a 1-year high of $4.45. The company’s 50-day moving average price is $2.10 and its 200 day moving average price is $2.63. The firm’s market capitalization is $50.55 million.

TRADEMARK VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://theolympiareport.com/2017/10/31/sunesis-pharmaceuticals-inc-snss-director-dayton-misfeldt-acquires-400000-shares-of-stock.html.

Large investors have recently added to or reduced their stakes in the business. Virtu KCG Holdings LLC purchased a new position in Sunesis Pharmaceuticals in the second quarter valued at about $208,000. Balyasny Asset Management LLC purchased a new position in Sunesis Pharmaceuticals in the second quarter valued at about $5,400,000. Vanguard Group Inc. raised its position in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the period. Wells Fargo & Company MN raised its position in Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares during the period. Finally, Sphera Funds Management LTD. raised its position in Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 68,212 shares during the period. 57.56% of the stock is currently owned by institutional investors.

Several research analysts recently commented on the company. Zacks Investment Research cut Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Cantor Fitzgerald reissued a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Thursday, July 27th. Finally, ValuEngine cut Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.